Research
Peptide storage and the cold chain
The storage numbers circulating for peptides come from chemical supplier data sheets, not from drug labels, and they differ enormously between compounds. Understanding what those temperatures protect against explains a shipping charge, a short use window, and part of what you are paying per milligram.
Where the numbers you have seen come from
Storage figures for peptides circulate widely and almost never carry a source. When FDA reviewed six peptides in July 2026, its chemists went and found those sources, and named them: supplier product data sheets and published literature.
The agency's phrasing is careful throughout, and the care is the point. It writes that a substance "is reported to be" stable under certain conditions, which describes a claim in a document rather than a tested specification for a finished medicine.
What follows is what that public record contains. It describes bulk substances, not anyone's product, and it is not a handling instruction. Storage directions for a medication come from the pharmacy that prepared it and the prescriber who ordered it.
Why the powder and the liquid are different products
Peptides are shipped as a lyophilized powder, meaning freeze-dried. Water is what makes them unstable, so removing it is how the material survives transport and time.
That is why every storage figure comes in two halves. There is a window for the sealed powder and a much shorter one for the solution after liquid has been added.
The gap between the two is large. For one of the compounds FDA reviewed, the reported powder window at freezer temperature is three years. The reported solution window at ordinary refrigerator temperature, for the same substance, is measured in weeks.
The numbers differ enormously between compounds
Anyone who has read one peptide storage chart tends to assume it generalizes. The records FDA assembled show it does not.
For KPV, the reported figures are up to three years for the powder at minus 20 degrees Celsius, up to two years at 4 degrees, and up to three months at 15 degrees. For TB-500 free base, a product data sheet reports two years at minus 80 degrees and one year at minus 20 degrees, sealed away from moisture and light under nitrogen.
For BPC-157 free base and for Epitalon free base, the literature reports the lyophilized powder is stable at room temperature for three weeks. Storage below minus 18 degrees is recommended, because moisture greatly decreases long-term stability. For MOTS-c free base, the reported condition is minus 20 degrees, desiccated, protected from light, in a tightly closed container.
Three weeks at room temperature and three years in a freezer are both real numbers about real substances, and neither one describes the other compound. The salt form of a compound also carries its own figures, different from the free base.
What the cold is protecting against
The risk is not that the molecule evaporates. It is that it changes shape and sticks to itself.
FDA states the mechanism the same way in review after review. Peptides can be extremely sensitive to formulation, process and environmental conditions, including pH, heat, concentration, in-process impurities and excipients, and those conditions can lead to aggregation and degradation. The consequence it names is loss of biological activity.
Aggregation matters for a second reason as well. Clumped peptide is the form most likely to provoke an immune response when injected, which is the concern the agency raised for every one of the six compounds it reviewed.
A degraded vial does not look different. There is no color change, no smell, and no visible signal that the material has changed.
Aggregates are hard to detect, and that is a systems problem
Measuring aggregation is not a matter of looking. FDA notes that multiple analytical methods may be needed to detect the various forms, including size exclusion chromatography and field flow fractionation.
It adds one clause that deserves attention, in its review of Epitalon. Such methods involve equipment that may not be available in a compounding facility.
That is a plain statement about capability. The test that would establish whether a peptide preparation has aggregated is not necessarily a test the place preparing it can run.
Why cold chain appears as its own charge
Temperature-controlled shipping is a separate operation from ordinary shipping. It uses insulated packaging and a coolant, it is time-sensitive, and it is often quoted separately from the medication price for exactly that reason.
A price comparison that ignores it will misread two providers. One folding cold-chain shipping into a single monthly figure looks more expensive than one quoting a lower medication price and adding the shipping at checkout.
The comparable figure is the total for a month with everything included. Shipping is one of the lines most often left outside the number a provider leads with.
The part of storage that shows up in price per milligram
Price per milligram is the right way to compare two sellers of the same compound. It quietly assumes the whole vial gets used.
A short window after a vial is opened breaks that assumption. Material discarded because a window closed was bought and not used, so the price per milligram actually used is higher than the price per milligram purchased.
That gap widens when the vial is large relative to what a person goes through in the window. A bigger vial can be cheaper per milligram bought and more expensive per milligram used, and only the second number describes what the treatment cost.
Where your own storage instruction comes from
A compounded medication carries the storage and use directions the pharmacy that prepared it assigned to it, based on how it was made and what it was made from. Those directions arrive with the product.
A research chemical supplier's data sheet is a document about bulk powder in a laboratory. It was not written about a preparation for a person, and it is not a substitute for the instruction that came with a prescription.
Where those two disagree, the one that came with the product is the one that describes the product.
Key takeaways
- Peptide storage figures in circulation come from supplier data sheets and literature, not from drug labels.
- Every compound carries two windows: one for the sealed powder and a much shorter one for the solution.
- Reported powder stability ranges from three weeks at room temperature to three years in a freezer, by compound.
- The risk being managed is aggregation and degradation, which cause loss of activity and raise immunogenicity risk.
- FDA noted the equipment needed to detect aggregates may not be available in a compounding facility.
- Cold-chain shipping and discarded material both sit outside the headline price and both change the real cost.
Frequently asked questions
Do peptides need to be refrigerated?
It depends entirely on the compound and on whether it is a sealed powder or a solution. FDA's July 2026 reviews record reported powder stability ranging from three weeks at room temperature for BPC-157 and Epitalon to three years at freezer temperature for KPV. Solutions carry much shorter windows in every case. Those are figures about bulk substances from supplier data sheets, and the directions for a specific medication come from the pharmacy that prepared it.
What actually happens to a peptide stored badly?
It aggregates and degrades. FDA describes peptides as extremely sensitive to temperature, pH, concentration, impurities and excipients, and names the result as loss of biological activity. Aggregated peptide also carries a higher risk of provoking an immune response when injected. None of this is visible in the vial, which is why the windows exist rather than a look-and-judge rule.
Can a pharmacy tell whether a batch has aggregated?
Detecting aggregates takes specific instruments, and FDA noted in its Epitalon review that the methods involved use equipment that may not be available in a compounding facility. The methods it named are size exclusion chromatography and field flow fractionation. That is a statement about what a facility can measure, not an accusation about any particular one.
Why is cold-chain shipping charged separately?
Because it is a different service with real costs: insulated packaging, coolant, and a delivery window that cannot slip. Providers structure that differently, and some absorb it into one monthly figure while others quote it at checkout. Neither approach is dishonest, and the split is a common reason two quotes look further apart than the totals actually are.
Does a short use window make a peptide more expensive than the price suggests?
It can. Price per milligram assumes the container gets used, and material discarded when a window closes was paid for without being used. The effect is largest when the vial holds much more than a person gets through inside the window. Comparing the price per milligram actually used, rather than purchased, is the version of the number that describes the cost.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- FDA Briefing Document for KPV-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee — U.S. Food and Drug Administration, May 2026
- FDA Briefing Document for TB-500-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee — U.S. Food and Drug Administration, May 2026
- FDA Briefing Document for BPC-157-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee — U.S. Food and Drug Administration, May 2026
- FDA Briefing Document for Epitalon-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee — U.S. Food and Drug Administration, May 2026
- FDA Briefing Document for MOTS-c-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee — U.S. Food and Drug Administration, May 2026